A Randomized, Placebo Controlled Clinical Trial of SOM230 (Pasireotide LAR) In Severe Polycystic Liver Disease.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2017
At a glance
- Drugs Pasireotide (Primary)
- Indications Polycystic liver disease
- Focus Therapeutic Use
- Acronyms SOM230
- 18 Oct 2017 Planned End Date changed from 1 Dec 2018 to 1 Jan 2019.
- 18 Oct 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2018.
- 01 Feb 2017 New trial record